Non-Alcoholic Fatty Liver Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight

DelveInsight's "Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Non-Alcoholic Fatty Liver Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Fatty Liver Disease Market Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Non-Alcoholic Fatty Liver Disease Market Report:
• The Non-Alcoholic Fatty Liver Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In December 2024, Galectin Therapeutics revealed the results from its global clinical trial, NAVIGATE, which assessed the effectiveness of belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
• In October 2024, PharmaIN Corporation announced that it will present interim results from its ongoing Phase I clinical trial of PHIN-214, its leading candidate, for the prevention and treatment of decompensated cirrhosis.
• The existing pipeline for NASH comprises a wide array of medications. FXR agonists, FGF21 stimulants, FGF19 analogs, glucagon-like peptide-1 (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR) regulators, THR-β agonists, and several others are among the prominent classes for this condition.
• According to the American Liver Foundation (2024), approximately 100 million people in the US-around 25% of the population-are estimated to have nonalcoholic fatty liver disease, now referred to as MASLD.
• According to the study conducted by Foschi et al. (2019), titled, "Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study," the prevalence of non-alcoholic fatty liver disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes
• Key Non-Alcoholic Fatty Liver Disease Companies: MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others
• The Non-Alcoholic Fatty Liver Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Fatty Liver Disease pipeline products will significantly revolutionize the Non-Alcoholic Fatty Liver Disease market dynamics.

Non-Alcoholic Fatty Liver Disease Overview
Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that encompasses the entire spectrum of fatty liver disease, from simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma.

Get a Free sample for the Non-Alcoholic Fatty Liver Disease Market Report -
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation:
The Non-Alcoholic Fatty Liver Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Non-Alcoholic Fatty Liver Disease
• Prevalent Cases of Non-Alcoholic Fatty Liver Disease by severity
• Gender-specific Prevalence of Non-Alcoholic Fatty Liver Disease
• Diagnosed Cases of Episodic and Chronic Non-Alcoholic Fatty Liver Disease

Download the report to understand which factors are driving Non-Alcoholic Fatty Liver Disease epidemiology trends @ Non-Alcoholic Fatty Liver Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-Alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Alcoholic Fatty Liver Disease Therapies and Key Companies
• MN-001: MediciNova
• LY3885125: Eli Lilly and Company
• AZD7503: AstraZeneca
• Lanifibranor: Inventiva Pharma
• OA-235i: Oasis Pharmaceuticals, LLC
• Resmetirom: Madrigal Pharmaceuticals, Inc.
• BMN 255: BioMarin Pharmaceutical
• GSK4532990: GlaxoSmithKline
• Saroglitazar Magnesium 4 mg Tablet: Zydus Therapeutics Inc.
• Efruxifermin: Akero Therapeutics, Inc
• PF-06865571: Pfizer
• BI 3006337: Boehringer Ingelheim
• DD01: Neuraly, Inc.
• Efinopegdutide: Merck Sharp & Dohme LLC
• HU6: Rivus Pharmaceuticals, Inc.
• Rencofilstat: Hepion Pharmaceuticals, Inc

Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Market Strengths
• Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed, that will strengthen the market

Non-Alcoholic Fatty Liver Disease Market Opportunities
• Lucrative opportunities for the market growth in United States, owing to presence of large pool of patients suffering from NASH

Scope of the Non-Alcoholic Fatty Liver Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Alcoholic Fatty Liver Disease Companies: MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others
• Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
• Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Alcoholic Fatty Liver Disease Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.